JAK inhibitors28–30 are used therapeutically to treat COVID-19 patients11,12,31 and our studies have identified IFN-induced genetic pathways that are suppressed by ruxolitinib and baricitinib. The gene discussed is IFNA1; the disease is COVID-19.